Management options for metastatic melanoma in the era of novel therapies: A primer for the practicing dermatologist : Part II: Management of stage IV disease - 14/12/12
Abstract |
Part II of this continuing medical education article will discuss the treatment options for stage IV melanoma, including novel therapies, such as ipilimumab and vemurafenib; established therapies, including high-dose interleukin-2, conventional chemotherapy, and biochemotherapy; and additional therapies currently under investigation in the form of clinical trials. The approach to patients with brain metastases will be discussed, as will recommendations for distress screening and defining aspects of palliative care.
Le texte complet de cet article est disponible en PDF.Key words : dacarbazine, distress thermometer, interleukin-2, ipilimumab, melanoma, vemurafenib
Abbreviations used : CTLA-4, DTIC, IL-2, OS, PD-1, SCC, SRS, WBRT
Plan
Funding sources: None. |
|
Dr Lao has served on an advisory board and as a speaker for Bristol-Myers Squibb and Genentech. |
Vol 68 - N° 1
P. 13.e1-13.e13 - janvier 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?